Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 microg/Week) and Ribavirin (1600 mg/Day) With Epoetin beta Support (450 IU/kg/Week)
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Epoetin beta
- Indications Hepatitis C; HIV infections
- Focus Therapeutic Use
- Acronyms CORAL2
- 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual end date changed from Oct 2007 to Mar 2009 as reported by ClinicalTrials.gov.
- 10 Feb 2009 Results presented at CROI 2009.